Public Wins

Public-Company Contract Wins

· 4 wins

SCYNEXIS Wins Federal Contract to Advance Antifungal SCY-247

major

SCYNEXIS INC (SCYX)

What it's for: Advance the development of SCY-247, a novel antifungal currently in Phase 1 clinical trials, for the treatment of invasive candidiasis and prophylaxis of invasive fungal disease as oral and IC formula.

This award equals about 89.58% of the company's annual revenue, a major contract for SCYNEXIS.

Awarded amount
$18,454,788
Agency
Department of Health and Human Services, Office of Assistant Secretary for Preparedness and Response
Materiality
89.58% of revenue

BK Technologies Wins $10,852,251.97 Forest Service Radio Contract

major

BK TECHNOLOGIES INC (BKTI)

What it's for: BK radios subscriber units.

This award equals about 12.6% of the company's annual revenue, a significant contract for BK Technologies.

Awarded amount
$10,852,251.97
Agency
Department of Agriculture, Forest Service
Materiality
12.60% of revenue

Telos Corporation Awarded $11,752,484 for HHS GRC and ATO Modernization

major

TELOS CORPORATION (TLS)

What it's for: Governance, risk, and compliance (GRC) and authority to operate (ATO) modernization for the Department of Health and Human Services (HHS), Office of the Chief Information Officer (OCIO), Office of Information Security (OIS).

This award equals about 7.13% of the company's annual revenue, a meaningful contract for Telos Corporation.

Awarded amount
$11,752,484
Agency
Department of the Interior, Departmental Offices
Materiality
7.13% of revenue

DLH Holdings Wins $3,765,381 NIH Task Order for Sister Study Analyses

notable

DLH HOLDINGS CORP (DLHC)

What it's for: Task order 02 award for chronic disease validation and analyses in the Sister Study.

This award equals about 1.09% of the company's annual revenue, a smaller but notable contract for DLH Holdings.

Awarded amount
$3,765,381
Agency
Department of Health and Human Services, National Institutes of Health
Materiality
1.09% of revenue

Data from USAspending.gov and SEC EDGAR. This is not investment advice.